Sun Pharmaceutical Industries , India’s largest drugmaker by revenue, reported a better-than-expected quarterly profit, powered by double-digit growth in its domestic business and robust demand across key therapeutic areas.

The Mumbai-based company’s consolidated net profit rose to ₹31.18 billion ($354.7 million) for the quarter ended September 30, compared with ₹30.4 billion a year earlier, surpassing analyst estimates of ₹29.97 billion. Revenue climbed 8.6% to ₹144.05 billion, aided by an 11% jump in India sales — its largest market.

While US revenue fell 4.1% to $496 million due to pricing pressure, analysts said Sun Pharma is well-positioned in that region thanks to new launches in alopecia and psoriasis treatments. Managing Director Kirti Ganorkar said the company aims for mid-to-h

See Full Page